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Abstract: Three new sesquiterpene aryl esters, named 10-dehydroxy-melleoliede B (1), 1-O-formyl-10-dehydroxy-melleoliede B 
(2) and 10-oxo-melleoliede B (3) together with six known ones (4–9), were isolated from the cultures of Armillaria sp. The  
structures of the new compounds were elucidated based on the extensive spectroscopic methods. Compounds 1, 2, and 5–9 exhibited
moderate cytotoxicities. 
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Introduction 
The basidiomycete genus Armillaria is recognized for the 
production of rich secondary metabolites with structure  
diversities as well as interesting biological activities.1 Among 
those metabolites, sesquiterpene aryl esters are quite a big 
family which showed antibacterial, antifungal activities,1c,1j 
and cytotoxicity.1o,1p As a part of our search for naturally  
occurring secondary metabolites with diverse structures from 
fungi in China,2 we have carried out the chemical investigation 
of Armillaria sp. cultures, which led to the isolation of three 
new sesquiterpene aryl esters, named 10-dehydroxy-
melleoliede B (1), 1-O-formyl-10-dehydroxy-melleoliede B 
(2), and 10-oxo-melleoliede B (3), together with melleolide B 
(4),1g 5'-chloromelleolide (5),1g armillarigin (6),1g armillarikin 
(7),1g A52a (8),3 and armillane (9).1p Those new compounds 
were elucidated by means of spectroscopic methods, while the 
known compounds were identified by comparison with data in 
the literature. All of these compounds were evaluated for  
cytotoxicity against five human cancer cell lines. 
 
Results and Discussion 
Compound 1, obtained as a colorless oil, had the molecular 
formula of C24H32O6 based on the negative-ion HRESIMS at 
m/z 415.2118 [M – H]– (calcd for C24H31O6, 415.2120). The IR 
data exhibited absorption bands for a hydroxy at 3430 cm–1, an 
ester group at 1646 cm–1 and a substituted aromatic ring at 
1617 cm–1 and 1578 cm–1,1 which consisted with the UV 
spectra. The 1H NMR spectrum (Table 1) of 1 exhibited one 
chelated phenolic hydroxy proton at δH 11.63, two aromatic 
protons at δH 6.31, one methoxy group at δH 3.80, four methyls 
including an aromatic one at δH 2.41. The 13C NMR spectrum 
revealed 24 carbons resonances (Table 2), which were 
classified into five methyl groups (three aliphatic, one 
oxygenated and one aromatic), four aliphatic methylenes (one 
oxygenated), six methines (three olefinic), and nine quaternary 
carbons (one carbonyl), indicating the presence of a tetra-
substituted benzene unit as well as one ester carbonyl signal at 
δC 171.8. The above data were quite closely related to those of 
melleolide B (4).1g The significant differences of the 13C NMR 
data between 1 and 4 were the lack of a secondary alcohol 
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signal and the presence of a methylene signal at δC 41.9 in 1, 
revealing the absence of HO-10 in 1. The above assumption 
was further confirmed by the 1H-1H COSY correlations of H-
10/H-9/H-13/H-12, and the HMBC correlations from H-10 to 
C-9, C-11, and C-13 (Figure 1). 
The ROESY correlations (Figure 1) of H-9/H-13, H-9/H-6β, 
H-5/H-6α, H-5/H-8, and H-6α/H-8 of 1, as well as the similar 
chemical shifts of the chiral carbons comparing with those of 
melleolide B, suggested the cis-anti-cis stereochemistry of the 
three rings.4 Therefore, the structure of compound 1 was 
established as 10-dehydroxy-melleoliede B. 
Compound 2, purified as a colorless oil, had a molecular 
formula of C25H32O7 according to its negative-ion HRESIMS 
at m/z 443.2070 ([M – H]–, calcd, 443.2069). The IR spectrum 
showed the presence of a hydroxy group at 3432 cm–1 and an 
ester moiety at 1629 cm–1.The 1D NMR (Tables 1 and 2) data 
were quite similar with those of 1 except for an additional 
signal for a formyl group (δH 7.87, δC 160.8). The formyl 
group attached at C-1 was confirmed by the HMBC of H-1 to 
C-CHO. Detailed analysis of 1D and 2D NMR data suggested 
that the other parts of 2 were the same to those of 1. Therefore, 
compound 2 was established as 1-O-formyl-10-dehydroxy-
melleoliede B. 
Compound 3, was obtained as a colorless oil. The negative-
ion HRESIMS afforded the molecular formula of C24H30O7 at 
m/z 429.1917 ([M – H]–, calcd, 429.1913). The IR data 
exhibited absorption bands for a hydroxy at 3431 cm–1, an 
ester group at 1642 cm–1 and a substituted aromatic ring at 
1618 cm–1 and 1579 cm–1, which were similar with those of 
compound 1. Detailed analysis of the 13C NMR suggested that 
the main difference between 3 and 1 was that a methine was 
oxidized into a keto carbonyl group at C 220.6 (C-10), which 
resulted in the downfield shift of C-9 ( 7.1 ppm), C-11 ( 
6.2 ppm) in compound 3. The above conclusion was supported 
by the HMBC correlations of H-9, H-13, and H-14 to C-10, 
and H-3 (δH 5.98) to C-12 (δC 41.9). Further analysis of 1D 
and 2D NMR data and coupling constants suggested that the 
other parts of the molecular was the same to compound 1. 
Thus, compound 3 was established as 10-oxo-melleoliede B. 
All compounds were evaluated for their cytotoxicity against 
five human cancer cell lines using the MTT method as reported
previously.5 Compounds 1, 2, and 5–9 showed cytotoxicities 
as shown in Table 3. It is notable that compound 2 showed 
stronger cytotoxicities than that of the positive control in 
MCF-7 and SW480 cell lines. 
Table 3. Cytotoxicity for compounds 1–9 (IC50, μM) 
Entry HL-60 SMMC-7721 A-549 MCF-7 SW480
1 17.79 20.90 16.79 16.49 17.44 
2 14.50 23.16 18.41 5.34 10.77 
3 > 40 > 40 > 40 > 40 > 40 
4 > 40 > 40 > 40 > 40 > 40 
5 > 40 > 40 20.11 30.06 > 40 
6 14.27 19.51 10.01 10.67 19.19 
7 14.11 17.41 14.73 11.52 19.89 
8 17.06 17.77 15.89 14.10 15.70 
9 20.27 30.36 16.62 16.56 > 40 
cisplatina 1.3 15.4 17.3 15.8 24.4 
aCisplatin was used as positive control. 
Table 1. 1H NMR data of 1–3 (1, 3 in Me2CO-d6 ; 2 in CDCl3) 
 
No. 
1 2 3 
δH (J in Hz) δH (J in Hz) δH (J in Hz) 
1 4.31, br. d (12.3); 4.03, dd (12.3, 2.9) 4.72, d (12.3); 4.60, d (12.3) 4.29, br. d (13.6); 4.00, br. d (13.6) 
3 5.77, br. s 5.90, br. s 5.98, br. s 
5 5.64, t (8.7) 5.48, t (8.7) 5.67, t (8.6) 
6 1.94, dd (11.2, 8.7); 1.70, dd (11.2, 8.7) 1.97, dd (11.1, 8.7); 1.77, dd (11.1, 8.7) 1.95, dd (11.3, 8.7); 1.73, dd (11.3, 8.7) 
8 1.25, s 1.28, s 1.64, s 
9 2.19, m 2.19, m 2.64, d (7.5) 
10 1.45, overlapped; 1.38, overlapped 1.44, overlapped; 1.24, overlapped  
12 1.86, dd (13.2, 8.5); 1.50, overlapped 1.85, dd (13.4, 8.7); 1.48, overlapped 2.09, overlapped; 1.91, br. d (13.0) 
13 2.78, br. t (7.8) 2.78, br. t (7.7) 3.13, br. t (7.5) 
14 1.00, s 0.95, s 0.99, s 
15 1.00, s 0.99, s 0.97, s 
3' 6.31, br. s 6.32, d (2.4) 6.31, br. s 
5' 6.31, br. s 6.26, d (2.4) 6.32, br. s 
7' 2.41, s 2.40, s 2.43, s 
OCH3 3.80, s 3.79, s 3.81, s 
Ar-OH 11.63, s 11.61, s 11.60, br. s 
CHO  7.87, s  
Figure 1.  Key HMBC, 1H–1H COSY, and ROESY 
correlations for 1 
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Experimental Section 
General Experimental Procedures. Optical rotations (OR) 
were recorded on a Jasco P-1020 digital polarimeter. UV and 
the IR spectra were obtained on a Shimadzu UV2401PC and a 
Bruker Tensor 27 FT-IR spectrometer with KBr pellets.  
Nuclear Magnetic Resonance (NMR) spectra were obtained on 
a BRUKER AM-400 and a BRUKER DRX-500 MHz  
spectrometer with tetramethylsilane (TMS) as an internal 
standard at room temperature. High-resolution (HR) ESIMS 
were recorded on an API QSTAR Pulsar spectrometer. Silica 
gel (200–300 mesh, Qingdao Marine Chemical Ltd., China) 
and Sephadex LH-20 (Amersham Biosciences, Sweden) were 
used for open column chromatography (CC). Preparative 
HPLC was performed on an Agilent 1100 liquid chromatog-
raphy system equipped with a Zorbax SB-C18 column (9.4 
mm × 150 mm). Fractions were monitored by TLC. Spots 
were visualized by heating silica gel plates immersed  
in Vanillin-H2SO4 in ethanol. 
 
Fungal Material and Cultivation Conditions. The fungus 
Arimillaria sp. was collected from Wuding, in Yunnan  
Province, China, in 2005. The culture medium consisted of 
glucose (5%), peptone from porcine meat (0.15%), yeast  
powder (0.5%), KH2PO4 (0.5%) and MgSO4. Fermentation 
was carried out on a shaker at 160RPM for 25 days. 
Extraction and Isolation. The culture broth (21 L) was  
filtered, and the filtrate was extracted three times with ethyl 
acetate, while the mycelium was extracted three times with 
CHCl3-MeOH (1:1). The EtOAc layer together with the  
mycelium extraction was concentrated under reduced pressure 
to give a crude extract (20 g), and this residue was chromato-
graphed on silica gel (200–300 mesh) column eluted with a 
gradient of CHCl3-MeOH (1:0 → 0:1) to obtain six fractions 
(1–6). Fraction 4 was subjected to a silica gel CC (petroleum 
ether-EtOAc, 6:1) to give 4 sub fractions (4a–4d). Subfraction 
4c was further purified by Sephadex LH-20 column (eluted 
with acetone) to give 2 (6 mg) while 4d was subjected to  
Sephadex LH-20 column (eluted with CHCl3-MeOH, 1:1) 
followed by semipreparative HPLC (MeCN-H2O, eluting from 
55:45 to 100:0 for 40 min with a flow rate of 10 mL/min) to 
yield 1 (14 mg) and 3 (11 mg). 
 
10-Dehydroxy-melleoliede B (1): colorless oil; [α]15D   + 41.4 
(c 1.08, MeOH); UV (MeOH) max (log ) 302 (3.73), 264 
(4.13), 215 (4.35) nm; IR (KBr) max 3430, 2949, 2864, 1646, 
1617, 1578, 1444, 1257, 1160 cm–1; 1H (400 MHz) and 13C 
NMR (100 MHz) data (Me2CO-d6), see Tables 1 and 2;  
negative ion HRESIMS m/z 415.2118 [M – H]– (calcd for 
C24H31O6, 415.2120). 
 
1-O-Formyl-10-dehydroxy-melleoliede B (2): colorless oil; 
[α]15D   + 29.4 (c 0.29, MeOH); UV (MeOH) max (log ) 302 
(3.72), 264 (4.12), 215 (4.35) nm; IR (KBr) max 3432, 2920, 
1629 cm–1; 1H (400 MHz) and 13C NMR (125 MHz) data 
(CDCl3), see Tables 1 and 2; negative ion HRESIMS m/z 
443.2070 ([M – H]–, calcd 443.2069). 
 
10-Oxo-melleoliede B (3): colorless oil; [α]15D   – 42.5 (c 0.28, 
MeOH); UV (MeOH) max (log ) 302 (3.70), 265 (4.10), 215 
(4.33) nm; IR (KBr) max 3431, 2928, 1730, 1642, 1618, 1579, 
1256, 1160 cm–1; 1H (400 MHz) and 13C NMR (100 MHz) 
data (Me2CO-d6), see Tables 1 and 2; negative ion HRESIMS 
m/z 429.1917 ([M – H]–, calcd 429.1913). 
 
Cytotoxicity Assay. Five human cancer cell lines, breast 
cancer MCF-7, hepatocellular carcinoma SMMC-7721, human 
myeloid leukemia HL-60, colon cancer SW480, and lung 
cancer A-549 cells, were used in the cytotoxic assay. All the 
cells were cultured in RPMI-1640 or DMEM medium 
(Hyclone, USA), supplemented with 10% fetal bovine serum 
(Hyclone, USA) in 5% CO2 at 37 C. The cytotoxicity assay 
was performed according to the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide) method in 96-well 
microplates.5 Briefly, 100 µL adherent cells were seeded into 
each well of 96-well cell culture plates and allowed to adhere 
for 12 h before drug addition, while suspended cells were 
seeded just before drug addition with initial density of 1 × 105 
cells/mL. Each tumor cell line was exposed to the test  
compound dissolved in DMSO at concentrations of 0.0625, 
0.32, 1.6, 8, and 40 μmol in triplicates for 48 h, with cisplatin 
(Sigma, USA) and vinorelbine (National Institute for the  
Control of Pharmaceutical and Biological Products, China) as 
positive controls. After compound treatment, cell viability was 
detected and a cell growth curve was graphed. IC50 values 
were calculated by Reed and Muench’s method.6 
 
Table 2. 13C NMR data of 1–3 (1, 3 in Me2CO-d6 ; 2 in CDCl3) 
 
No. 
1 2 3 
δC mult δC mult δC mult 
1 65.2, t 64.1, t 63.9, t 
2 135.2, s 130.2, s 140.3, s 
3 132.8, d 137.9, d 131.0, d 
4 77.6, s 77.6, s 77.7, s 
5 79.4, d 77.9, d 79.4, d 
6 33.4, t 32.2, t 34.7, t 
7 39.4, s 38.5, s 39.3, s 
8 22.0, q 21.7, q 20.4, q 
9 45.3, d 44.0, d 52.4, d 
10 41.9, t 41.5, t 220.6, s 
11 38.4, s 37.9, s 44.6, s 
12 48.4, t 47.4, t 41.9, t 
13 39.9, d 39.2, d 35.0, d 
14 32.3, q 31.8, q 28.2, q 
15 32.2, q 31.7, q 27.4, q 
1' 105.9, s 104.6, s 105.9, s 
2' 166.3, s 165.7, s 166.4, s 
3' 99.5, d 98.8, d 99.5, d 
4' 165.0, s 164.2. s 165.5, s 
5' 111.6, d 111.3, d 111.5, d 
6' 144.1, s 143.0, s 144.3, s 
7' 24.2, q 24.2, q 24.3, q 
8' 171.8, s 171.3, s 171.8, s 
OCH3 55.7, q 55.3, q 55.8, q 
CHO  160.8, d  
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